Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$11.76 USD
+0.17 (1.47%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $11.74 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MLYS 11.76 +0.17(1.47%)
Will MLYS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for MLYS
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Mineralys Therapeutics Inc (MLYS) Q2 2024 Earnings Call Transcript Highlights: Significant ...
Stifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)